Neubase Therapeutics Stock Price To Earning
| NBSEDelisted Stock | USD 1.62 0.17 9.50% |
NeuBase Therapeutics fundamentals help investors to digest information that contributes to NeuBase Therapeutics' financial success or failures. It also enables traders to predict the movement of NeuBase Stock. The fundamental analysis module provides a way to measure NeuBase Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NeuBase Therapeutics stock.
NeuBase |
NeuBase Therapeutics Company Price To Earning Analysis
NeuBase Therapeutics' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current NeuBase Therapeutics Price To Earning | (4.17) X |
Most of NeuBase Therapeutics' fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NeuBase Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
CompetitionBased on the latest financial disclosure, NeuBase Therapeutics has a Price To Earning of -4.1726 times. This is 116.15% lower than that of the Biotechnology sector and 184.64% lower than that of the Health Care industry. The price to earning for all United States stocks is 114.53% higher than that of the company.
NeuBase Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NeuBase Therapeutics' direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NeuBase Therapeutics could also be used in its relative valuation, which is a method of valuing NeuBase Therapeutics by comparing valuation metrics of similar companies.NeuBase Therapeutics is currently under evaluation in price to earning category among its peers.
NeuBase Fundamentals
| Return On Equity | -0.93 | |||
| Return On Asset | -0.43 | |||
| Current Valuation | (5.83 M) | |||
| Shares Outstanding | 3.75 M | |||
| Shares Owned By Insiders | 13.37 % | |||
| Shares Owned By Institutions | 12.68 % | |||
| Number Of Shares Shorted | 15.57 K | |||
| Price To Earning | (4.17) X | |||
| Price To Book | 0.18 X | |||
| EBITDA | (32.49 M) | |||
| Net Income | (33.78 M) | |||
| Cash And Equivalents | 29.85 M | |||
| Cash Per Share | 0.93 X | |||
| Total Debt | 6 M | |||
| Debt To Equity | 0.20 % | |||
| Current Ratio | 7.53 X | |||
| Book Value Per Share | 2.45 X | |||
| Cash Flow From Operations | (29.01 M) | |||
| Short Ratio | 0.24 X | |||
| Earnings Per Share | (18.60) X | |||
| Price To Earnings To Growth | (0.07) X | |||
| Target Price | 140.0 | |||
| Number Of Employees | 37 | |||
| Beta | 0.95 | |||
| Market Capitalization | 1.42 M | |||
| Total Asset | 32.69 M | |||
| Retained Earnings | (102.74 M) | |||
| Working Capital | 20.48 M | |||
| Current Asset | 4.14 M | |||
| Current Liabilities | 1.6 M | |||
| Net Asset | 32.69 M |
About NeuBase Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NeuBase Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NeuBase Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NeuBase Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in NeuBase Stock
If you are still planning to invest in NeuBase Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NeuBase Therapeutics' history and understand the potential risks before investing.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |